Galapagos Genomics First clinical centers opened for Phase 2 Crohn's study with GLPG0634
- First selective JAK1 inhibitor to enter Phase 2 in Crohn's disease
- 180 patients to be enrolled for 20 weeks of treatment
- Topline data expected in Q2 2015
- Galapagos eligible for $50 M success fee from AbbVie upon study completion
- 180 patients to be enrolled for 20 weeks of treatment
- Topline data expected in Q2 2015
- Galapagos eligible for $50 M success fee from AbbVie upon study completion